Personalis (PSNL) to Release Quarterly Earnings on Tuesday

Personalis (NASDAQ:PSNL - Get Free Report) is anticipated to issue its Q1 2025 quarterly earnings data after the market closes on Tuesday, May 6th. Analysts expect the company to announce earnings of ($0.23) per share and revenue of $17.41 million for the quarter. Personalis has set its FY 2025 guidance at EPS and its Q1 2025 guidance at EPS.

Personalis (NASDAQ:PSNL - Get Free Report) last announced its earnings results on Thursday, February 27th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.32) by $0.09. Personalis had a negative net margin of 104.52% and a negative return on equity of 66.07%. The company had revenue of $16.80 million during the quarter, compared to analyst estimates of $15.48 million. On average, analysts expect Personalis to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Personalis Stock Up 7.8 %

PSNL traded up $0.30 during trading on Friday, hitting $4.16. The company's stock had a trading volume of 960,158 shares, compared to its average volume of 982,838. The business's 50 day simple moving average is $3.62 and its 200-day simple moving average is $4.46. The firm has a market cap of $367.36 million, a PE ratio of -2.48 and a beta of 1.83. Personalis has a one year low of $1.14 and a one year high of $7.20.

Wall Street Analyst Weigh In

PSNL has been the subject of a number of analyst reports. HC Wainwright restated a "buy" rating and issued a $8.00 price target on shares of Personalis in a research report on Friday, February 28th. Needham & Company LLC reissued a "buy" rating and issued a $7.00 target price on shares of Personalis in a report on Thursday, April 10th. Lake Street Capital raised their target price on shares of Personalis from $7.00 to $9.00 and gave the stock a "buy" rating in a research note on Wednesday, January 8th. Finally, Craig Hallum assumed coverage on shares of Personalis in a research report on Monday, March 17th. They issued a "buy" rating and a $8.00 price target for the company. Five analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has an average rating of "Buy" and an average price target of $7.80.

Personalis Company Profile

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.